References
- Steinberg M, Shao H, Zandi P, et al. Cache County Investigators. Point and five-year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriatr Psychiatry 2008;23:170-7
- Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr 2010;22(03):346-72
- Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer’s disease: controversies and possible solutions. Curr Opin Psychiatry 2009;22(6):532-40
- Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement 2013;9(5):602-8
- Kales HC, Gitlin LN, Lyketsos CG, et al. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a Multidisciplinary Expert Panel. J Am Geriatr Soc 2014;62(4):762-9
- Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011;(2):CD008191
- Small GW. Treating dementia and agitation. JAMA 2014;311(7):677-8
- Melrose RJ, Ettenhofer ML, Harwood D, et al. Cerebral metabolism, cognition, and functional abilities in Alzheimer disease. J Geriatr Psychiatry Neurol 2011;24(3):127-34
- Sultzer DL, Leskin LP, Melrose RJ, et al. Neurobiology of Delusions, Memory, and Insight in Alzheimer Disease. Am J Geriatr Psychiatry 2013. [Epub ahead of print]
- McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 2005;4(11):735-42
- Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014;311(7):682-91
- Sheline YI, West T, Yarasheski K, et al. An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice. Sci Transl Med 2014;6(236):236re4
- Zivin K, Pfeiffer PN, Bohnert AS, et al. Safety of high-dosage citalopram. Am J Psychiatry 2014;171(1):20-2
- Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study. Int Psychogeriatr 2011;23(09):1515-19
- Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15(11):942-52
- Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006;355(15):1525-38